The importance of neoangiogenesis in soft tissue tumours is confirmed by the arising number of publications comparing angiogenesis mediators [VEGF (vascular endothelial growth factor), angiogenin, etc.] with clinical features (tumour grade, tendency to metastasize, response to treatment, overall survival and risk of recurrence) of patients with STS. The gene discussed is VEGFA; the disease is soft tissue neoplasm.